Ductal carcinoma in situ (DCIS) encompasses a highly heterogeneous group of lesions that
differ with regard to their clinical presentations, histologic features, biomarker profiles …

Background The natural history of ductal carcinoma in situ (DCIS) remains uncertain. The
risk factors for the development of invasive cancer in unresected DCIS are unclear. Methods …

Ductal carcinoma in situ (DCIS) of the breast is a nonobligate precursor of invasive breast
cancer, accounting for 20% of screen‐detected breast cancers. Little is known about the …

Tumor-infiltrating lymphocytes (TILs) provide prognostic value in invasive breast cancer and
guidelines for their assessment have been published. This study aims to evaluate:(a) …

Background The role of different subtypes of tumour infiltrating lymphocytes (TILs) in breast
ductal carcinoma in situ (DCIS) is still poorly defined. This study aimed to assess the …

Abstract Background Approximately 8–56% of patients with a core needle biopsy (CNB)
diagnosis of ductal carcinoma in situ (DCIS) will be upstaged to invasive disease at the time …

Background To develop an ultrasound-based deep learning model to predict postoperative
upgrading of pure ductal carcinoma in situ (DCIS) diagnosed by core needle biopsy (CNB) …

Purpose Although ductal carcinoma in situ (DCIS) seldom involves lymph nodes, some
patients may upstage to invasive disease, thus requiring a second surgery for sentinel lymph …

The high proportion of ductal carcinoma in situ (DCIS) presented in mammographic
screening and the relatively low risk of progression to invasive disease have raised …

Background Approximately 30% of patients with an initial diagnosis of ductal carcinoma
ductal in situ (DCIS) present stromal invasion in the final surgical specimen. This study …